Number of the records: 1  

Discovery of the first dual inhibitor of the 5-lipoxygenase-activating protein and soluble epoxide hydrolase using pharmacophore-based virtual screening

  1. 1.
    SYSNO ASEP0474823
    Document TypeJ - Journal Article
    R&D Document TypeJournal Article
    Subsidiary JČlánek ve WOS
    TitleDiscovery of the first dual inhibitor of the 5-lipoxygenase-activating protein and soluble epoxide hydrolase using pharmacophore-based virtual screening
    Author(s) Temml, V. (AT)
    Garscha, U. (DE)
    Romp, E. (DE)
    Schubert, G. (DE)
    Gerstmeier, J. (DE)
    Kutil, Zsófia (UEB-Q)
    Matuszczak, B. (AT)
    Waltenberger, B. (AT)
    Stuppner, H. (AT)
    Werz, O. (DE)
    Schuster, D. (AT)
    Number of authors11
    Article number42751
    Source TitleScientific Reports. - : Nature Publishing Group - ISSN 2045-2322
    Roč. 7, FEB 20 (2017)
    Number of pages8 s.
    Languageeng - English
    CountryGB - United Kingdom
    Keywordsactivating protein ; drug discovery ; leukotriene biosynthesis ; inflammatory diseases ; conformer generation ; arachidonic-acid ; flap ; challenges ; asthma ; risk
    Subject RIVCE - Biochemistry
    OECD categoryPhysiology (including cytology)
    Institutional supportUEB-Q - RVO:61389030
    UT WOS000394419900001
    DOI10.1038/srep42751
    AnnotationLeukotrienes (LTs) are pro-inflammatory lipid mediators derived from arachidonic acid (AA) with roles in inflammatory and allergic diseases. The biosynthesis of LTs is initiated by transfer of AA via the 5-lipoxygenase-activating protein (FLAP) to 5-lipoxygenase (5-LO). FLAP inhibition abolishes LT formation exerting anti-inflammatory effects. The soluble epoxide hydrolase (sEH) converts AA-derived anti-inflammatory epoxyeicosatrienoic acids (EETs) to dihydroxyeicosatetraenoic acids (diHETEs). Its inhibition consequently also counteracts inflammation. Targeting both LT biosynthesis and the conversion of EETs with a dual inhibitor of FLAP and sEH may represent a novel, powerful anti-inflammatory strategy. We present a pharmacophore-based virtual screening campaign that led to 20 hit compounds of which 4 targeted FLAP and 4 were sEH inhibitors. Among them, the first dual inhibitor for sEH and FLAP was identified, N-[4-(benzothiazol-2-ylmethoxy)-2-methylphenyl]-N'-(3,4-dichlorophenyl) urea with IC50 values of 200 nM in a cell-based FLAP test system and 20 nM for sEH activity in a cell-free assay.
    WorkplaceInstitute of Experimental Botany
    ContactDavid Klier, knihovna@ueb.cas.cz, Tel.: 220 390 469
    Year of Publishing2018
Number of the records: 1  

  This site uses cookies to make them easier to browse. Learn more about how we use cookies.